Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. develops and commercializes autoimmune diagnostic testing products under the AVISE brand. The company’s flagship AVISE CTD test is used by clinicians in evaluating complex rheumatic and autoimmune diseases, including lupus, rheumatoid arthritis and Sjögren’s disease, and its CLIA-certified, CAP-accredited laboratory specializes in rheumatic disease testing.
Recurring news for XGN includes quarterly and annual financial results, AVISE CTD test volume, average selling price, revenue, gross margin and cash updates. Company announcements also cover autoimmune biomarker research, additions to the AVISE testing portfolio, conference participation and corporate updates tied to Exagen’s diagnostics business.
Exagen Inc. (Nasdaq: XGN) announced that all AVISE test offerings are now an in-network service with Tufts Medical Center. This collaboration aims to enhance the accuracy and accessibility of autoimmune disease testing. John Butz from Tufts emphasized the need for better diagnostic options for autoimmunity. Ron Rocca, CEO of Exagen, noted that this agreement will significantly improve patient care through better diagnosis and monitoring capabilities. The partnership is expected to facilitate faster diagnosis and treatment interventions for complex autoimmune diseases.
Exagen Inc. (Nasdaq: XGN) reported preliminary financial results for Q4 2020, projecting testing revenue between $10.5 million and $10.8 million, reflecting an 11% to 15% increase from Q3 2020. The company delivered approximately 28,600 AVISE CTD tests, backed by a record 635 healthcare provider adopters and a 99% retention rate. Despite COVID-19 challenges, Exagen's core testing business showed strong performance, positioning it for growth in 2021. Full financial results, including SIMPONI revenue, will be released in March 2021.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN) is set to participate in the 2021 ICR Conference from January 11-14, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will hold a virtual fireside chat on January 14 at 11:30 AM ET. Attendees can schedule one-on-one meetings with management during the event. Exagen focuses on transforming care for patients with autoimmune diseases through innovative testing products, aiming to enable timely diagnosis and therapeutic intervention.
Exagen Inc. (Nasdaq: XGN) has announced that all AVISE test offerings are now contracted as in-network services with St. Charles Health System, the largest healthcare provider in Central Oregon. This partnership is expected to enhance patient care by making AVISE testing accessible to rheumatologists for the diagnosis and monitoring of autoimmune diseases, especially systemic lupus erythematosus (SLE). CEO Ron Rocca highlighted the significance of this arrangement for improving community health outcomes.
Exagen Inc. (Nasdaq: XGN) announced its participation in key December investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will feature a recorded company presentation available from November 23 to December 3, 2020. Additionally, Ron Rocca, the President and CEO, will engage in a Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 10:30 am EST. Exagen focuses on advancing care for patients with autoimmune diseases, utilizing its innovative AVISE® testing products.
Exagen Inc. (Nasdaq: XGN) has extended its collaboration agreement with GlaxoSmithKline (GSK) to improve the diagnosis of systemic lupus erythematosus (SLE), a major autoimmune disease. This partnership aims to enhance awareness of the importance of early diagnosis, which currently takes an average of nearly six years. The agreement will continue to utilize Exagen's proprietary AVISE® laboratory tests to support SLE patients in achieving better health outcomes. The details of the agreement remain confidential, following a similar extension made last year.
Exagen Inc. (Nasdaq: XGN) reported strong Q3 2020 results with revenue of $10.8 million, reflecting a 20% increase from Q2 2020 and a 3% rise year-over-year. Despite COVID-19 challenges, the company delivered 26,201 AVISE® tests and achieved a 99% retention rate among healthcare providers. Significant additions of 14 million covered lives were made, enhancing testing access. Although net loss increased to $4.3 million, gross margin improved to 60%. Exagen continues to strengthen its market position through innovative products and strategic partnerships.
Exagen Inc. (Nasdaq: XGN) announced management participation in November investor conferences to enhance its presence in the healthcare sector. They will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:00 pm EST and engage in a Fireside Chat at the Canaccord Genuity MedTech & Diagnostics Forum on November 19, 2020, at 11:30 am EST. Exagen focuses on innovative testing for autoimmune diseases and aims to improve care through its AVISE® brand products.
Exagen Inc. (Nasdaq: XGN) has partnered with Brigham and Women’s Hospital to study the incidence and risk factors of rheumatic autoimmune diseases in COVID-19 survivors. The year-long study will involve positive PCR-confirmed COVID-19 patients categorized by disease severity. Participants will complete questionnaires and undergo testing with AVISE® biomarkers to assess new rheumatic disease symptoms and autoantibody formation. This research aims to clarify the association between COVID-19 recovery and autoimmune disease development, addressing current knowledge gaps in this area.
Exagen Inc. (Nasdaq: XGN) will announce its financial results for the quarter ending September 30, 2020, on November 10, 2020, after market close. The conference call, led by CEO Ron Rocca and CFO Kamal Adawi, will begin at 4:30 PM ET. Investors can join the call by dialing (877) 407-3982 or via webcast on the Exagen investor relations website. A replay will be accessible until November 17, 2020. Exagen focuses on enhancing care for patients with autoimmune diseases through innovative testing products under its AVISE® brand.